Abstract
Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancers. This study characterized the absorption, distribution, metabolism, and elimination (ADME) of rucaparib in six patients with advanced solid tumors following a single 600 mg oral dose of [14C]-rucaparib. Total radioactivity (TRA) and unchanged rucaparib were tracked in blood, plasma, urine, and feces. Results showed a mean recovery of 89.3% of the dose over 12 days, with feces being the primary route of elimination (71.9%). Rucaparib and its oxidative metabolite, M324, were the major components identified. These findings suggest that rucaparib is cleared through multiple redundant pathways, including hepatic metabolism and renal/biliary excretion.
Introduction
Understanding the pharmacokinetic (PK) "budget" of a therapeutic agent is essential for clinical safety, particularly for predicting drug-drug interactions and adjusting dosages for patients with renal or hepatic impairment. Rucaparib, an FDA-approved therapy for BRCA-mutated cancers, requires a clear map of its metabolic breakdown and clearance organs. This study provides the first published human mass balance for rucaparib, accounting for the drug's complete journey through the body to ensure optimal clinical use.
Methods
In this Phase I, open-label study, six female patients with advanced solid tumors received a single oral 600 mg dose of rucaparib containing approximately 140 μCi of [14C]-radioactivity. Total Radioactivity (TRA) was measured in biological samples over a 12-day period using Liquid Scintillation Counting (LSC). Unchanged rucaparib and its metabolites were quantified and identified using validated LC-MS/MS and Orbitrap mass spectrometry. Pharmacokinetic parameters were calculated via non-compartmental analysis.
Results
Pharmacokinetics and Plasma Distribution
Rucaparib was absorbed with a median peak plasma concentration ($C_{max}$) occurring at approximately 4 hours post-dose. The terminal half-life for both TRA and unchanged rucaparib exceeded 25 hours, supporting the current clinical twice-daily dosing schedule. The blood-to-plasma ratio of radioactivity was approximately 1.0 at $C_{max}$, indicating an even distribution between plasma and red blood cells.
As shown in the concentration-time profiles, the curves for TRA and unchanged rucaparib were parallel, suggesting that metabolites are formed and cleared at rates similar to the parent drug. The higher concentration of TRA compared to rucaparib in plasma confirms the presence of circulating metabolites.
Excretion and Mass Balance
The study achieved a high degree of mass balance, with a mean total recovery of 89.3% of the radioactive dose. Fecal excretion was the dominant pathway, accounting for 71.9% of the dose, while renal excretion accounted for 17.4%.
The high fecal recovery is attributed to a combination of unabsorbed drug and biliary excretion of absorbed drug. In feces, rucaparib remained largely unchanged (63.9% of dose), whereas in urine, rucaparib and the metabolite M324 were the primary components (each ~7.6% of dose).
Metabolism
Metabolic profiling identified M324, an oxidative metabolite, as the primary breakdown product. In plasma, rucaparib accounted for 64.0% of the radioactivity, while M324 contributed 18.6%. The study confirms that rucaparib is cleared through redundant pathways involving CYP-mediated hepatic metabolism, renal filtration, and biliary excretion.
Discussion and Limitations
This study successfully mapped the ADME profile of rucaparib, highlighting its multi-pathway clearance. While the small sample size (n=6) is standard for human radiolabeled studies, it may not capture full inter-patient variability across different demographics. Additionally, while fecal excretion is the major route, the exact proportion of unabsorbed drug versus biliary-excreted drug remains to be precisely quantified. Future research will continue to evaluate the clinical impact and specific PK profile of the M324 metabolite.
Summary updated